Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bone. 2021 Feb;143:115794. doi: 10.1016/j.bone.2020.115794. Epub 2020 Dec 8.
Hypophosphatasia (HPP) is a hereditary musculoskeletal disorder caused by inactivating variants in the ALPL gene and subsequently reduced serum tissue-nonspecific alkaline phosphatase (TNSALP) activity. This inborn error of metabolism results in decreased bone quality, accumulations of osteoid, and reduced bone mineralization. Increased incidence of fractures and prolonged bone healing are characteristic features for HPP. Available enzyme replacement therapy (asfotase alfa), was reported to recover bone mineralization and bone quality in adult HPP patients. Moreover, it was shown that asfotase alfa improved fracture healing of former nonunions in two adult HPP patients. We hypothesized that the nonunions are filled partially with osteoid, offering great potential to benefit from the treatment with asfotase alfa to promote bone healing. In the present study, we report three adult patients with pediatric-onset HPP and detected ALPL-mutations with prolonged bone healing after arthrodesis, tibial stress fracture, and osteotomy. After the initiation of asfotase alfa, immediately increased levels of alkaline phosphatase (ALP) and bone-specific ALP, as well as decreased levels of pyridoxal-5-phosphate (PLP), were detected in biochemical analysis. Importantly, even after up to 5 years of non-healing, a progredient consolidation was shown, assessed by a custom three-dimensional evaluation of repeated cone-beam computed tomography (CBCT) images, characterized by rapidly increasing levels of bone volume per tissue volume (BV/TV) within the volume of interest (i.e., the region of the non-healing bone). These radiographical findings were in line with the reported restoration of functional ability and pain-free full weight-bearing, as well as increased neuromuscular parameters (e.g., improved muscle strength). Taken together, our findings indicate that asfotase alfa improves the osseous consolidation of nonunions likely due to re-mineralization of osteoid tissue filling the former gap and improving the functional ability in adult HPP patients, characterized by increasing levels of BV/TV assessed via an innovative three-dimensional evaluation of CBCT images.
低磷酸酯酶症(HPP)是一种遗传性肌肉骨骼疾病,由 ALPL 基因的失活变异引起,随后导致血清组织非特异性碱性磷酸酶(TNSALP)活性降低。这种先天性代谢错误导致骨质量下降、类骨质堆积和骨矿化减少。骨折发生率增加和骨愈合延长是 HPP 的特征。已报道的酶替代疗法(阿法特酶)可恢复成人 HPP 患者的骨矿化和骨质量。此外,研究表明,阿法特酶可改善两名成人 HPP 患者先前骨不连的骨折愈合。我们假设骨不连部分被类骨质填充,为从阿法特酶治疗中受益以促进骨愈合提供了巨大潜力。在本研究中,我们报告了 3 名儿童期发病的 HPP 成年患者,这些患者在融合、胫骨应力性骨折和截骨术后出现骨愈合延长,并检测到 ALPL 突变。在开始使用阿法特酶后,在生化分析中立即检测到碱性磷酸酶(ALP)和骨特异性 ALP 水平升高,以及吡哆醛-5-磷酸(PLP)水平降低。重要的是,即使在长达 5 年的不愈合后,也显示出进行性巩固,通过对重复锥形束 CT(CBCT)图像的定制三维评估进行评估,其特征是在感兴趣的体积(即不愈合骨的区域)内的骨体积/组织体积(BV/TV)水平迅速增加。这些影像学发现与报告的功能能力恢复、无痛全负重和神经肌肉参数增加(例如,肌肉力量增强)相一致。总之,我们的发现表明,阿法特酶可改善骨不连的骨整合,可能是由于填充先前间隙的类骨质组织再矿化,从而改善成年 HPP 患者的功能能力,通过对 CBCT 图像的创新三维评估,BV/TV 水平增加。